<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572767</url>
  </required_header>
  <id_info>
    <org_study_id>2000/001</org_study_id>
    <secondary_id>2000/030</secondary_id>
    <nct_id>NCT00572767</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke</brief_title>
  <official_title>Evaluation of the Therapeutic Effect of Amphetamine in Association to Physiotherapy on Motor Recovery After Stroke: a Randomised, Double-Blinded, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reha Rheinfelden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reha Rheinfelden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of Dextro-amphetamin added to physiotherapy on&#xD;
      motor recovery in patients after stroke. The study is a double-blinded placebo-controlled&#xD;
      randomised controlled trial.&#xD;
&#xD;
      Patients after a first-ever ischemic stroke will receive Dexamphetamine (10mg) twice per week&#xD;
      for a duration of five weeks after a baseline phase of two weeks.&#xD;
&#xD;
      The outcome measure focuses on motor recovery and will be assessed:&#xD;
&#xD;
        -  one and two weeks before study intervention (baseline phase)&#xD;
&#xD;
        -  five times during the study intervention&#xD;
&#xD;
        -  one week after study intervention (follow-up)&#xD;
&#xD;
        -  once after six and twelve months after start of the study intervention (follow-up).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Intended length of study ended&#xD;
  </why_stopped>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chedoke-McMaster Stroke Assessment (motor impairment measure)</measure>
    <time_frame>Over the whole duration of the study (2001 to 2006, ten times for each patient)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextro-Amphetamin</intervention_name>
    <description>After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.&#xD;
The treatment of the control group will be the same as for the experimental group except the content of the drug capsule.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients after first-ever ischemic stroke with a clinical relevant paresis of the&#xD;
             upper and lower limb (general clinical muscle testing below level four)&#xD;
&#xD;
          -  correlation of clinical symptoms with a brain imaging (CT or MRI)&#xD;
&#xD;
          -  able to communicate with the neurological examiner and understand the aim/matter of&#xD;
             the study (with or without aphasia)&#xD;
&#xD;
          -  start of the first oral application of the study drug between the fourteenth and 60th&#xD;
             day after stroke onset&#xD;
&#xD;
          -  older than 13 years&#xD;
&#xD;
          -  given written informed consent (or two independent witnesses)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intracranial or (chronic) subdural hemorrhages&#xD;
&#xD;
          -  any additional neurological or psychiatric illnesses&#xD;
&#xD;
          -  instable arrythmia&#xD;
&#xD;
          -  not controlled or treated arterial hypertension&#xD;
&#xD;
          -  ensured cardioembolic event&#xD;
&#xD;
          -  anxiolytica, neuroleptica, or alpha-adrenergic antagonists or agonists respectively&#xD;
&#xD;
          -  certain anticonvulsiva or antihypertonica&#xD;
&#xD;
          -  manifest hyperthyreosis&#xD;
&#xD;
          -  dementia or terminal illnesses&#xD;
&#xD;
          -  epilepsy, phaeochromocytoma or glaucoma&#xD;
&#xD;
          -  women known to be pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry M. Ettlin, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reha Rheinfelden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reha Rheinfelden</name>
      <address>
        <city>Rheinfelden</city>
        <state>AG</state>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2007</last_update_posted>
  <responsible_party>
    <name_title>Ettlin, Th. Prof.</name_title>
    <organization>Reha Rheinfelden</organization>
  </responsible_party>
  <keyword>randomised-controlled trial</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>motor recovery</keyword>
  <keyword>amphetamine</keyword>
  <keyword>motor recovery of patients after a first-ever ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

